MAPLIGHT THERAPEUTICS INC

Insider buying in MAPLIGHT THERAPEUTICS shows executives betting on future growth—RSU and option buys signal confidence amid a volatile stock.

Catalyst4’s recent bulk purchase of MAPLIGHT Therapeutics shares and warrants signals confidence in the company’s pipeline and growth prospects, offering a bullish outlook amid market volatility.

Insider sales by MAPLIGHT’s CSO reveal cautious liquidity tactics amid a 63% stock drop and regulatory scrutiny, hinting at potential downside rather than confidence.

Catalyst4’s recent $10‑$13 share buys show insider confidence in MAPLIGHT, hinting at undervalued upside amid a shaky quarter.

MapLight Therapeutics insider buying signals potential upside: Troy Cox purchases shares amid volatile market and promising Phase 2 results.

MAPLIGHT insider selling is routine tax‑cover, not a distress signal. CEO’s bulk trades keep ownership above 1.3 M shares, while the pipeline stays strong.

MapLight insiders sell 35,000+ shares at $28‑$30, yet keep confidence high amid a 71% YTD rise, showing risk‑managed gains rather than alarm.

MapLight insiders sell 11 M+ shares tax‑driven; 12.4% weekly rally and 68% monthly gain raise volatility concerns but signal no immediate decline.

MapLight insiders sell shares to cover RSU taxes, while executives buy back—investors see modest supply pressure, but potential upside from Q3 2026 clinical data.

MapLight insider sales reveal steady ownership and disciplined tax‑related selling—no panic signs, but watch the 180‑day lock‑up for a supply shock.